O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy - PubMed (original) (raw)

Affiliations

PMID: 10213216

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy

J R Silber et al. Clin Cancer Res. 1999 Apr.

Abstract

The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) contributes to the resistance of human brain tumor cell lines and xenografts to methylating and chloroethylating agents. We assayed MGMT in 174 newly diagnosed or recurrent gliomas to (a) quantitate changes in MGMT activity associated with alkylating agent-based chemotherapy; and (b) assess the contribution of MGMT to clinical outcome. Glioma MGMT activity ranged 300-fold, averaging 3,800+/-7,200 molecules/cell. Twenty-four percent of tumors lacked detectable activity [Methyl repair-deficient (Mer-) phenotype, defined here as <151 molecules/cell or <0.25 fmol/10(6) cells]. Tumors treated with surgery alone and tumors recurring after surgery and radiotherapy did not differ significantly in frequency of the Mer- phenotype (29% versus 24%). However, the frequency of the Mer- phenotype among tumors recurring after surgery, radiation, and alkylating agent-based chemotherapy was 7-fold lower than in tumors treated with surgery alone (4.3% versus 29%; P < or = 0.02) and 6-fold lower than in tumors recurring after surgery and radiation (4.3% versus 24%; P < or = 0.05). In contrast to gliomas, there was no relationship of alkylating agent-based therapy with the frequency of the Mer- phenotype in paired histologically normal brain. These data suggest that alkylating agents, either alone or synergistically with radiotherapy, selectively kill Mer- glioma cells in situ. Importantly, Mer- and Mer+ tumors did not differ in time to tumor progression following treatment with alkylating agents, indicating that although Mer- glioma cells may be differentially killed by alkylators, factors other than Mer phenotype were the principal determinants of time to clinical progression. Nonetheless, our results support the possibility that complete ablation of glioma MGMT with substrate analogue inhibitors could improve the efficacy of alkylating agent-based chemotherapy.

PubMed Disclaimer

Cited by

Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.
Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Pouratian N, et al. J Neurooncol. 2007 May;82(3):281-8. doi: 10.1007/s11060-006-9280-4. Epub 2006 Nov 3. J Neurooncol. 2007. PMID: 17082887
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K; Cancer Genome Atlas Research Network. Noushmehr H, et al. Cancer Cell. 2010 May 18;17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. Epub 2010 Apr 15. Cancer Cell. 2010. PMID: 20399149 Free PMC article.
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG, McDonald KL. Parkinson JF, et al. J Neurooncol. 2008 Mar;87(1):71-8. doi: 10.1007/s11060-007-9486-0. Epub 2007 Nov 15. J Neurooncol. 2008. PMID: 18004504
Chemotherapy for malignant gliomas.
Marosi C. Marosi C. Wien Med Wochenschr. 2006 Jun;156(11-12):346-50. doi: 10.1007/s10354-006-0307-4. Wien Med Wochenschr. 2006. PMID: 16944366 Review.
Cancer drug resistance: redox resetting renders a way.
Liu Y, Li Q, Zhou L, Xie N, Nice EC, Zhang H, Huang C, Lei Y. Liu Y, et al. Oncotarget. 2016 Jul 5;7(27):42740-42761. doi: 10.18632/oncotarget.8600. Oncotarget. 2016. PMID: 27057637 Free PMC article. Review.

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy - PubMed (original) (raw)